What question did this study set out to answer?

To evaluate the efficacy and tolerability of alternating CHOP-Bleo and CMED chemotherapy with radiation therapy for Ann Arbor Stages II-IV intermediate-grade lymphomas, and to assess prognostic models for risk stratification.

May 1, 1994Cancer

Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis

View Full Paper

Ask AI

Bookmark

Authors

WVWilliam S. VelasquezTexas Medical Center PMPeter McLaughlinHeidelberg University LFLillian M. FullerTexas Medical Center

Discussion

Member takes

Implication

Clinical trial demonstrates improved survival using alternating CHOP-Bleo and CMED in intermediate-grade lymphoma, suggesting risk models effectively categorize outcomes.

Key Points

To evaluate the efficacy and tolerability of alternating CHOP-Bleo and CMED chemotherapy with radiation therapy for Ann Arbor Stages II-IV intermediate-grade lymphomas, and to assess prognostic models for risk stratification.
Treated 170 patients presenting with Ann Arbor Stages II-IV intermediate-grade lymphoma with 12 total alternating cycles of CHOP-Bleo and CMED.
Interspersed involved-field radiation therapy with chemotherapy courses for patients diagnosed with Stage II and Stage III disease.
Stratified and compared patient outcomes against previous CHOP-Bleo protocols using Ann Arbor staging, a prior institutional prognostic model, and the International Index.
Achieved a complete remission rate of 78% across all patients, with an overall 5-year survival rate of 67%.
Observed higher 5-year survival in Stage II disease (80%) compared to Stage III (67%) and Stage IV (58%), with high tumor burden, elevated LDH, and elevated beta 2-microglobulin acting as significant adverse prognostic factors.
Treatment was generally well tolerated, though neutropenic fever occurred in 25 patients, resulting in 6 sepsis-related deaths.

Cite This Study

Velasquez et al. (1994) studied this question.

synapsesocial.com/papers/6a9239c8808ea93e70c7fb8d https://doi.org/10.1002/1097-0142(19940501)73:9<2408::aid-cncr2820730926>3.0.co;2-m

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial demonstrates improved survival using alternating CHOP-Bleo and CMED in intermediate-grade lymphoma, suggesting risk models effectively categorize outcomes.

Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider